SCHEMBL4833248

SCHEMBL4833248

Cc1ccc(-c2c(/C=C/C(=O)O)cnn2C)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNC P24863 3/20 0.50
CDK8 P49336 3/20 0.50
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
KDM4E B2RXH2 7/20 0.48
RAB9A P51151 7/20 0.48
ALDH1A1 P00352 7/20 0.48
NPC1 O15118 6/20 0.48
HPGD P15428 6/20 0.48
SMN1; SMN2 Q16637 5/20 0.48
MAPT P10636 7/20 0.44
TP53 P04637 2/20 0.44
PTGS1 P23219 3/20 0.43
IP6K1 Q92551 1/20 0.42
IP6K3 Q96PC2 1/20 0.42
IP6K2 Q9UHH9 1/20 0.42
LMNA P02545 5/20 0.42
CASP3 P42574 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4833261 1.00 CCNC (0.50) CCNCCDK8MEN1KMT2AKDM4E
SCHEMBL4829098 0.88 PTGS1 (0.54) CCNCCDK8MEN1KMT2AKDM4E
SCHEMBL4829106 0.88 PTGS1 (0.54) CCNCCDK8MEN1KMT2AKDM4E
SCHEMBL4825825 0.87 CCNC (0.49) CCNCCDK8KDM4ERAB9AALDH1A1
SCHEMBL4833832 0.87 CCNC (0.49) CCNCCDK8KDM4ERAB9AALDH1A1
SCHEMBL4831077 0.87 CCNC (0.49) CCNCCDK8MEN1KMT2AKDM4E
SCHEMBL4831079 0.87 CCNC (0.49) CCNCCDK8MEN1KMT2AKDM4E
SCHEMBL4826921 0.87 CCNC (0.49) CCNCCDK8MEN1KMT2AKDM4E
SCHEMBL4825815 0.87 CCNC (0.49) CCNCCDK8KDM4ERAB9AALDH1A1
SCHEMBL4826934 0.87 CCNC (0.49) CCNCCDK8MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287438-A1 Agent for preventing or treating neuropathy MOMOSE YU 2008-11-20 US disclosed
US-7423159-B2 Agent for preventing or treating neuropathy TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-09-09 US disclosed
US-20060004069-A1 Agent for preventing or treating neuropathy TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-01-05 US disclosed
EP-1556032-A1 AGENT FOR PREVENTING OR TREATING NEUROPATHY Takeda Pharmaceutical Company Limited (JP) 2005-07-27 EP disclosed
WO-2004039365-A1 AGENT FOR PREVENTING OR TREATING NEUROPATHY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-05-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004069-A1 Agent for preventing or treating neuropathy NR2C2, NR0B2, NR2E1 CCNC 2548/4885CDK8 2963/4885MEN1 3516/4885
US-20080287438-A1 Agent for preventing or treating neuropathy NR2C2, NR0B2, NR2E1 CCNC 2548/4885CDK8 2963/4885MEN1 3516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.